ClinicalTrials.gg
Sign In

Inflammatory Breast Neoplasms clinical trials

The registry lists 112 studies for Inflammatory Breast Neoplasms across more than 10 countries. 7 are recruiting or about to start. 53 of them are mainly about Inflammatory Breast Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Inflammatory Breast Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
54
Terminated
17
Active, not recruiting
15
Status unknown
15
Recruiting
6
Withdrawn
4

Phase

Phase 2
62
Phase 1
22
Phase 3
17
Early Phase 1
2

Where

United States
78
United Kingdom
10
Canada
7
Germany
7
Belgium
7
France
6

Who runs them

M.D. Anderson Cancer Center (17) · National Cancer Institute (NCI) (11) · City of Hope Medical Center (6) · German Breast Group (5) · Dana-Farber Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · RenJi Hospital (3) · H. Lee Moffitt Cancer Center and Research Institute (2)

What is being tested here

Drugs under test in Inflammatory Breast Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Trastuzumab deruxtecan101
Durvalumab101
Paclitaxel0419
Cyclophosphamide0216
Docetaxel0212
Carboplatin0211
Trastuzumab0211
Epirubicin0010
Albumin-Bound Paclitaxel028
Doxorubicin018

Drug classes tested here Immune checkpoint inhibitors 1 open · Antimitotic agents 34 · Alkylating agents 17 · Tyrosine kinase inhibitors (TKIs) 10 · Angiogenesis inhibitors 10

Coming up

1phase 3 study under way
5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Who these studies take

Of the 6 Inflammatory Breast Neoplasms studies recruiting now, 5 (83%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 3 (50%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 6
AgeWomenMen
100 (0%)0 (0%)
186 (100%)3 (50%)
306 (100%)3 (50%)
406 (100%)3 (50%)
506 (100%)3 (50%)
656 (100%)3 (50%)
756 (100%)3 (50%)
856 (100%)3 (50%)

Across all 112 studies, recruiting or not: 20% stop at 75 or younger and 9% at 65; 8% take children; 56% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Inflammatory Breast Neoplasms studies take

Of 21 phase 2 interventional studies under Inflammatory Breast Neoplasms, half reached primary completion within 94 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 294 mo63–109 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 112. Browse all 112 → or search them.